NeurologyLive® Friday 5 — January 30, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: Assessing Psychiatric Comorbidities in Functional Seizures Under New AAN Guidelines: Benjamin Tolchin, MD, FAAN

In a recent interview, Benjamin Tolchin, MD, FAAN, director of the Center for Clinical Ethics at Yale New Haven Health, provided insights on newly published guidelines for functional seizures, stressing the reasons for systemic psychiatric assessment and careful seizure characterization. [WATCH TIME: 3 minutes]

2: Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial

This month’s Clinical Trial in Focus exclusive spotlight feature is the phase 2 REVISE trial (NCT07303296) of lenadogene nolparvovec (Lumevoq; GenSight Biologics), also known as GS010, for patients with Leber hereditary optic neuropathy (LHON), a rare genetic disorder that leads to bilateral vision loss.

3: Managing Postpartum MS: Safety Data, Relapse Risk, and Real-World Practice

In this initial podcast episode, host Lindsay Ross, MD, is joined by Edith Graham, MD, assistant professor of neurology at Northwestern University Feinberg School of Medicine, for an in-depth discussion on managing multiple sclerosis during breastfeeding. [LISTEN TIME: 40 minutes]

4: NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026

In our latest NeuroVoices Q&A, Kathrin LaFaver, MD, FAAN, DipABLM, a neurologist in the Department of Neurology at Saratoga Hospital Medical Group, shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

5: Integrating AI and Translational Science to Advance ALS Care: Crystal Yeo, MD, PhD

In an interview at AANEM 2025, Crystal Yeo, MD, PhD, a consultant neurologist at the National Neuroscience Institute, discussed how artificial intelligence, biomarker development, and drug repurposing can help improve patient care in ALS. [WATCH TIME: 4 minutes]

Click here to view more video interviews with neurology experts.